# Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical

- Link: https://www.thailand-business-news.com/pr-news/nova-biomedical-advances-integrated-cell-line-development-workflows-nanocellect-products-are-now-part-of-nova-biomedical
- Published: 2026-07-24T21:05:00+07:00
- Author: PR Newswire

WALTHAM, Mass., July 24, 2026 /PRNewswire/ — Nova Biomedical today announced a transaction
involving certain assets of NanoCellect, a provider of microfluidic cell sorting
technology.

This expands Nova Biomedical’s capabilities in cell line development and strengthens
its ability to support biopharmaceutical workflows from early development through
manufacturing.

NanoCellect^(®) WOLF G2^(®) cell sorting platform introduces gentle, microfluidic-
based cell selection and isolation, complementing Nova Biomedical’s existing Solentim
portfolio for clone generation, verification, and growth analysis. Together, these
technologies enable a more integrated approach to cell line development—linking 
cell selection, single-cell isolation, and high-confidence clone verification.

This expansion of Nova’s portfolio will accelerate cell line development timelines
and improve clone selection outcomes, while establishing a stronger foundation for
process development, scale-up, and manufacturing.

Nova Biomedical’s portfolio also includes robust analytical solutions for cell culture
monitoring, including metabolite analysis with BioProfile^(®) FLEX2, osmolality 
measurement with OsmoTECH^(®), and cell counting and viability with BioProfile^(
®) FAST CDV. These capabilities serve as critical control points across the bioprocessing
workflow and are used from development through production.

The addition of the NanoCellect products further advances Nova Biomedical’s strategy
to provide a more connected portfolio of technologies supporting continuity, insight,
and decision-making across the full bioprocessing lifecycle.

"NanoCellect adds a critical upstream capability to our portfolio and strengthens
our ability to connect key steps in cell line development," said John Luck, President
of Nova Biomedical’s Biopharma Business. "By integrating cell sorting with clone
isolation and high-confidence verification, alongside analytical control points 
such as cell culture monitoring and osmolality, we are enabling customers to reach
a successful clone more quickly and generate insights that help optimize clone selection
and drive better performance during process development, scale-up, and manufacturing.
This is an important step in building a more connected and differentiated platform
for cell line development and bioprocessing."

**About Nova BiomedicalNova Biomedical is a global provider of advanced analytical
instruments and solutions for the biopharmaceutical and clinical markets. The company’s
portfolio supports critical workflows across cell line development, process development,
and manufacturing, enabling customers to improve productivity, quality, and operational
efficiency.

**About NanoCellectNanoCellect develops microfluidic cell sorting technologies designed
for gentle, sterile cell isolation. Its platforms are used in applications including
cell line development, single-cell analysis, and cell therapy research.

Lisa Fahey

VP, Corporate Programs and Communications

Email: [lfahey@novabio.com](https://www.thailand-business-news.com/pr-news/lfahey@novabio.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical ](http://www.prnasia.com/story/archive/5011725_AE11725_0?rand=184833)